Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

32.43 +1.66 (+5.39%)
Streaming Delayed Price Updated: 11:44 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
Via Benzinga
Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to... 
Via Benzinga
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
From The Rosen Law Firm PA
Via GlobeNewswire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 12, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
NATIONALLY RANKED ROSEN LAW FIRM Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 10, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Via ACCESSWIRE
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 04, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 04, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 02, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Via ACCESSWIRE
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and  
Via Benzinga
Catalent (CTLT) Stock Gains on Elliott Deal
Catalent (CTLT) stock is getting a boost on Tuesday after the company reached an agreement with Elliott Investment Management. 
Via InvestorPlace
Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts
Apellis Pharmaceuticals (APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.